Blood, Hair, Urine, Vaginal fluids, Saliva, Semen

Zika Virus

Sosecali Ltd. (SOSE)

Fundacao Oswaldo Cruz (FIOCRUZ)

University of Sao Paulo

Industrial University of Santander (UIS)

Pedro Kouri Institute (IPK)

INSERM

IMSS Mexico (IMSS)

National Institute of Public Health (INSP)

Universidad de Carabobo / UMC Groningen (UMCG)

ZIKAlliance Children Cohort (ZIKAllianceCH)

Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy

The ZIKAlliance birth cohort is part of the 3 European Commission (EC) funded Zika consortia. The data are intended to be shared after the individual cohort data is analyzed and published.
The ZIKAlliance birth cohort is part of the WHO-moderated IPD meta-analysis Consortium. The data are intended to be shared after the individual cohort data is analyzed and published.

Thomas Jaenisch

University of Heidelberg Medical Center

child born to mothers with proved zika virus in pregnancy by RT-PCR

Child born with symptoms similar to babies proved exposed to zika virus but mothers without symptoms or positive RT-PCR

Normal child from mothers without Zika (IgG and IgM negative)

Urine and blood for RT-PCR Blood for IgG and IgM Saliva for RT-PCR placenta oral swab for genetic studies fetal tissues stillborn for necropsy CSF and amniotic fluid if affected babies breastmilk

ZIKA VIRUS INFECTION

Child Development

Microcephaly

There will be applied Bayley Teste 3rd edition

Child exposed Zika virus proved

Instituto Fernandes Figueira/Fiocruz

Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)

Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF

Microcephaly at birth or delay in development in Bayley test 3rd edition at 12, 18 and between 24-36 months of age

ocular injury in eye exam by indirect ophtalmoscopia registe by RetCam associated with cognitive disorder

deaphness or BERA abnomalities associated to language disorder

we will share the data with Brazilian Minister of Health, WHO and European ZikaPlane consortium

Oswaldo Cruz Foundation

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Rio de Janeiro State Research Supporting Foundation (FAPERJ)

Pregnancy Related

Federal University of Bahia (UFB)

Universidade Federal de Minas Gerais

Federal University of Goias

ZIKAlliance Pregnant Women Cohort

Pregnant Women (PW) Cohort for Evaluation of Risks of Congenital Malformations and Other Adverse Pregnancy Outcomes After Zika Virus Infection (Part of ZIKAlliance)

The ZIKAlliance birth cohort is part of the 3 EC-funded Zika consortia. The data are intended to be shared after the individual cohort data is analyzed and published.
The ZIKAlliance birth cohort is part of the WHO-moderated IPD meta-analysis Consortium. The data are intended to be shared after the individual cohort data is analyzed and published.

Senior Scientist

European Union

ZIKAlliance

London School of Hygiene and Tropical Medicine

Federal University of Bahia

Universidade Federal de Goias

University Medical Center Groningen

University of Carabobo

Universidad Industrial de Santander

Sosecali Hospital, Guyaquil

Tropical Medicine Institute Pedro Kourí, Cuba

Mexican National Institute of Public Health

Instituto Mexicano del Seguro Social

Institut National de la Santé Et de la Recherche Médicale, France

Erasmus Medical Center

ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 8.

ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 12.

ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0, Week 4 and Week 8.

ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0,Week 4 and Week 20.

Prevention of Zika Infection

Zika-Specific Immune Response

VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.

VRC-ZKADNA085-00-VP

Hope Clinic - Emory Vaccine Ctr

University of Maryland Ctr. for Vaccine Development

National Institutes of Health Clinical Center

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

microcephaly/kuume

ZIKAlliance Children Cohort (ZIKAllianceCH)

Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)

ZIKAlliance Pregnant Women Cohort

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

Täydellisin lääketieteellinen tietokanta tieteen tukemana